The progressive state, in contrast to the stable or regressive state of alopecia areata, is reflected in peripheral blood mononuclear cells

Experimental Dermatology

Volumn 13, Issue 7, 2004, Pages 435-444

  Zöller, Margot ^a,b   McElwee, Kevin J ^c   Vitacolonna, Mario ^a   Hoffmann, Rolf ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF KARLSRUHE   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Autoimmunity; Cell surface molecules; Contact sensitizer; Human; T lymphocytes

Indexed keywords

B7 ANTIGEN; CD16 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; DIPHENCYPRONE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ALOPECIA AREATA; ARTICLE; AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL COMPOSITION; CLINICAL ARTICLE; CONTACT SENSITIZATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENETIC SUSCEPTIBILITY; HAIR LOSS; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SCHOOL CHILD; SKIN INFLAMMATION; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ADOLESCENT; ADULT; AGED; ALOPECIA AREATA; ANTIGENS, CD40; ANTIGENS, CD80; CD40 LIGAND; CHILD; CYCLOPROPANES; CYTOKINES; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; LIGANDS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, IGG; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4043145727     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2004.00179.x     Document Type: Article

References (58)

1. Perret C, Wiesner-Menzel L, Happle R. Immunohistochemical analysis of T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata. Acta Derm Venereol 1984: 64: 26-30.
2. Racke M K, Stuart R W. Targeting T cell costimulation in autoimmune disease. Expert Opin Ther Targets 2002: 6: 275-289.
3. Paus R, Slominski A, Czarnetzki B M. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med 1993: 66: 541-554.
4. McElwee K J, Boggess D, King Jr L E, Sundberg J P. Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest Dermatol 1998: 111: 797-803.
5. Randall V A. Is alopecia areata an autoimmune disease? Lancet 2001: 358: 1922-1924.
6. Carroll J M, McElwee K J, King L, Byrne MC, Sundberg J P. Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol 2002: 119: 392-402.
7. + T cells restores hair growth in the DEBR model for alopecia areata. Br J Dermatol 1996: 135: 211-217.
8. + T cells. Br J Dermatol 1999: 140: 432-437.
9. Gilhar A, Krueger G G. Hair growth in scalp grafts from patients with alopecia areata and alopecia universalis grafted onto nude mice. Arch Dermatol 1987: 123: 44-50.
10. Gilhar A, Ullmann Y, Berkutzki T, Assy B, Kalish R S. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest 1998: 101: 62-67.
11. Gilhar A, Landau M, Assy B, Shalaginov R, Serafimovich S, Kalish R S. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc (scid) mice. J Invest Dermatol 2001: 117: 1357-1362.
12. Tobin D J, Orentreich N, Fenton D A, Bystryn J C. Antibodies to hair follicles in alopecia areata. J Invest Dermatol 1994: 102: 721-724.
13. McElwee K J, Pickett P, Oliver R F. The DEBR rat, alopecia areata and autoantibodies to the hair follicle. Br J Dermatol 1996: 134: 55-62.
14. Tobin D J, Sundberg J P, King Jr L E, Boggess D, Bystryn J C. Autoantibodies to hair follicles in C3H/HeJ mice with alopecia areata-like hair loss. J Invest Dermatol 1997: 109: 329-333.
15. Freyschmidt-Paul P, Hoffmann R, Levine E, Sundberg J P, Happle R, McElwee K J. Current and potential agents for the treatment of alopecia areata. Curr Pharm Des 2001: 7: 213-230.
16. Freyschmidt-Paul P, Happle R, McElwee K J, Hoffmann R. Alopecia Areata: Treatment of today and tomorrow. J Investig Dermatol Symp Proc 2003: 8: 12-17.
17. McElwee K J, Hoffmann R. Alopecia areata - animal models. Clin Exp Dermatol 2002: 27: 414-421.
18. McElwee K J, Hoffmann R. Alopecia areata susceptibility in rodent models. J Investig Dermatol Symp Proc (in press).
19. Zöller M, McElwee K J, Engel P, Hoffmann R. Transient CD44 variant isoform expression and reduction in CD4(+)/CD25(+) regulatory T cells in C3H/HeJ mice with alopecia areata. J Invest Dermatol 2002: 118: 983-992.
20. + cells. J Invest Dermatol 2002: 119: 1426-1433.
21. Yano S, Nakamura K, Okochi H, Tamaki K. Analysis of the expression of cutaneous lymphocyte-associated antigen on the peripheral blood and cutaneous lymphocytes of alopecia areata patients. Acta Derm Venereol 2002: 82: 82-85.
22. Hordinsky M K, Hallgren H, Nelson D, Filipovich A H. Suppressor cell number and function in alopecia areata. Arch Dermatol 1984: 120: 188-194.
23. + T-lymphocyte population in peripheral blood of alopecia areata. Clin Exp Dermatol 1991: 16: 176-180.
24. Valsecchi R, Bontempelli M, Vicari O, Frigeni A, Foiadelli L, Cainelli T. Peripheral T-cell subsets in patients with alopecia areata in different clinical phases. Dermatologica 1985: 171: 170-174.
25. Galbraith G M, Thiers B H, Vasily D B, Fudenberg H H. Immunological profiles in alopecia areata. Br J Dermatol 1984: 110: 163-170.
26. Baadsgaard O, Lindskov R. Circulating lymphocyte subsets in patients with alopecia areata. Acta Derm Venereol 1986: 66: 266-268.
27. Ledesma G N, York K K. Suppressor cell decrease in alopecia areata. Arch Dermatol Res 1982: 274: 1-8.
28. Majewski B B, Koh M S, Taylor D R, Watson B, Rhodes E L. Increased ratio of helper to suppressor T cells in alopecia areata. Br J Dermatol 1984: 110: 171-175.
29. Lutz G, Niedecken H, Bauer R, Kreysel H W. Two-color flow cytometry analysis in alopecia areata. Dermatologica 1989: 178: 64-66.
30. + cell lymphopenia in patients with alopecia areata. Indian J Med Res 1996: 104: 296-298.
31. Olsen E, Hordinsky M, McDonald-Hull S et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol 1999: 40: 242.
32. Cotellessa C, Peris K, Caracciolo E, Mordenti C, Chimenti S. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol 2001: 44: 73-76.
33. Van der Steen P H, Happle R. Topical immunotherapy of alopecia areata. Dermatol Clin 1993: 11: 619-622.
34. Schuhmacher J, Klivenyl G, Matys R, Stadler M, Reglert T, Hauser H, Doll J, Maier-Borst W, Zöller M. Multistep tumour targeting in nude mice using bispecific antibodies and a Gallium chelate suitable for Immunoscintigraphy with PET. Cancer Res 1995: 55: 115-123.
35. Imai R, Miura J, Numata K, Takamori K. Increase in natural killer cells in the peripheral blood lymphocytes in patients with alopecia areata. Nippon Hifuka Gakkai Zasshi 1988: 98: 1505-1507.
36. Beyan H, Buckley L R, Yousaf N, Londei M, Leslie R D. A role for innate immunity in type 1 diabetes? Diabetes Metab Res Rev 2003: 19: 89-100.
37. Lee P T, Putnam A, Benlagha K, Teyton L, Gottlieb P A, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002: 110: 793-800.
38. Kukreja A, Cost G, Marker J et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002: 109: 131-140.
39. Hickey W F, Ueno K, Hiserodt J C, Schmidt R E. Exogenously-induced, natural killer cell-mediated neuronal killing: a novel pathogenetic mechanism. J Exp Med 1992: 176: 811-817.
40. Nilsson N, Carlsten H. Enhanced natural but diminished antibody-mediated cytotoxicity in the lungs of MRL1pr/1pr mice. Clin Exp Immunol 1996: 105: 480-485.
41. Kitaichi N, Kotake S, Morohashi T, Onoe K, Ohno S, Taylor A W. Diminution of experimental autoimmune uveoretinitis (EAU) in mice depleted of NK cells. J Leukoc Biol 2002: 72: 1117-1121.
42. Burger D, Dayer J M. Cytokines, acute-phase proteins, and hormones: IL-1 and TNF-alpha production in contact-mediated activation of monocytes by T lymphocytes. Ann N Y Acad Sci 2002: 966: 464-473.
43. Smyth M J, Johnstone R W. Role of TNF in lymphocyte-mediated cytotoxicity. Microsc Res Tech 2000: 50: 196-208.
44. Vujanovic N L. Role of TNF family ligands in anti-tumor activity of natural killer cells. Int Rev Immunol 2001: 20: 415-437.
45. Sundberg J P, Boggess D, Silva K A et al. Major locus on mouse chromosome 17 and minor locus on chromosome 9 are linked with alopecia areata in C3H/HeJ mice. J Invest Dermatol 2003: 120: 771-775.
46. Galbraith G M, Pandey J P. Tumor necrosis factor alpha (TNF-alpha) gene polymorphism in alopecia areata. Hum Genet 1995: 96: 433-436.
47. Cork M J, Crane A M, Duff G W. Genetic control of cytokines: Cytokine gene polymorphisms in alopecia areata. Dermatol Clin 1996: 14: 671-678.
48. McElwee K J, Freyschmidt-Paul P, Ziegler A, Happle R, Hoffmann R. Genetic susceptibility and severity of alopecia areata in human and animal models. Eur J Dermatol 2001: 11: 11-16.
49. McDonagh A J, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol 2002: 27: 405-409.
50. Chang T T, Kuchroo V K, Sharpe A H. Negative co-receptors on lymphocytes. Curr Opin Immunol 2002: 14: 391-396.
51. Greenwald R J, Latchman Y E, Sharpe A H. Role of the B7-CD28/CTLA-4 pathway in autoimmune disease. Curr Dir Autoimmun 2002: 5: 113-130.
52. Schwartz J C, Zhang X, Nathenson S G, Almo S C. Structural mechanisms of costimulation. Nat Immunol 2002: 3: 427-434.
53. Chinen J, Shearer W T. Basic and clinical immunology. J Allergy Clin Immunol 2003: 111: S813-S818.
54. Mosmann T R, Coffman R L. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989: 46: 111-147.
55. Mosmann T R, Moore K W. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 1991: 12: A49-A53.
56. Freyschmidt-Paul P, McElwee K J, Happle R et al. Interleukin-10-deficient mice are less susceptible to the induction of alopecia areata. J Invest Dermatol 2002: 119: 980-982.
57. Ulrich P, Vohr H W. Murine lymph node antigen presenting cells are the main source of interleukin-6 in the initiation of delayed-type hypersensitivity. Eur Cytokine Netw 1996: 7: 401-407.
58. Kobayashi K, Kaneda K, Kasama T. Immunopathogenesis of delayed-type hypersensitivity. Microsc Res Tech 2001: 53: 241-245.